The Kuwait Ministry of Health has issued Price Resolution No. 93/2025, approving pricing for 69 medicines across a wide range of therapeutic categories, including treatments for cancer, diabetes, hypertension, cardiovascular diseases, neurology (Alzheimer’s, migraines, epilepsy), and more. This decision is part of a broader strategy to standardize medicine prices and enhance affordability in the private sector.

📨 Launching or marketing new products in Kuwait’s?
Let ReguLinked help you align pricing, regulatory compliance, and market positioning for successful entry.